Myriad Genetics, Inc. (MYGN)
Stock Price Chart
Key Info
| Market Cap | 1.40B |
| Revenue (ttm) | 597.50M |
| Net Income (ttm) | -194.10M |
| Shares Out | 75.21M |
| EPS (ttm) | -2.61 |
| PE Ratio | n/a |
| Forward PE | 370.37 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 1 |
| Last Price | $18.66 |
| Previous Close | $17.54 |
| Change ($) | 1.12 |
| Change (%) | 6.39% |
| Day's Open | 17.76 |
| Day's Range | 17.46 - 18.87 |
| Day's Volume | 674,794 |
| 52-Week Range | 9.78 - 29.53 |
More Stats
| Market Cap | 1.40B |
| Enterprise Value | 1.53B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 75.21M |
| Float | n/a |
| EPS (basic) | -2.61 |
| EPS (diluted) | -2.61 |
| FCF / Share | -0.33 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 9.91M |
| Short Ratio | 15.89 |
| Short % of Float | n/a |
| Beta | 1.46 |
| PE Ratio | n/a |
| Forward PE | 370.37 |
| P/FCF Ratio | n/a |
| PS Ratio | 2.35 |
| PB Ratio | 1.51 |
| Revenue | 597.50M |
| Operating Income | -255.00M |
| Net Income | -194.10M |
| Free Cash Flow | -24.70M |
| Net Cash | -131.30M |
| Net Cash / Share | -1.75 |
| Gross Margin | 75.73% |
| Operating Margin | -42.68% |
| Profit Margin | -32.50% |
| FCF Margin | -4.13% |
| ROA | -6.40% |
| ROE | -19.58% |
| ROIC | -42.50% |
Analyst Forecasts
Analyst Consensus: Hold
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 639 | 851 | 744 | 729 | 741 | 723 | 778 | 613 | 496 | 402 |
| Revenue Growth | -24.97% | 14.44% | 2.06% | -1.59% | 2.41% | -7.08% | 26.91% | 23.63% | 23.36% | - |
| Gross Profit | 453 | 650 | 567 | 558 | 583 | 576 | 669 | 534 | 431 | 355 |
| Operating Income | -235 | 8.70 | 60.70 | 43.20 | 153 | 134 | 274 | 228 | 180 | 158 |
| Net Income | -200 | 4.60 | 133 | 17.40 | 117 | 80.20 | 176 | 147 | 112 | 101 |
| Shares Outstanding | 74.30 | 73.50 | 69.40 | 68.30 | 70.00 | 71.30 | 75.70 | 80.90 | 84.61 | 89.79 |
| Earnings Per Share | -2.69 | 0.06 | 1.85 | 0.25 | 1.60 | 1.08 | 2.25 | 1.77 | 1.30 | 1.10 |
| EPS Growth | - | -96.76% | 640% | -84.38% | 48.15% | -52% | 27.12% | 36.15% | 18.18% | - |
| Operating Cash Flow | 60.70 | 83.70 | 116 | 106 | 166 | 141 | 190 | 174 | 142 | 131 |
| Capital Expenditures | -10.20 | -8.60 | -8.40 | -6.10 | -5.00 | -23.90 | -14.30 | -11.40 | -9.41 | -3.79 |
| Free Cash Flow | 50.50 | 75.10 | 108 | 100 | 161 | 117 | 176 | 163 | 132 | 127 |
| Cash & Equivalents | 218 | 137 | 181 | 151 | 159 | 145 | 186 | 372 | 341 | 346 |
| Total Debt | 295 | 234 | 9.30 | 99.10 | - | - | - | - | - | - |
| Net Cash / Debt | -77.00 | -96.60 | 171 | 51.60 | 159 | 145 | 186 | 372 | 341 | 346 |
| Assets | 1,405 | 1,563 | 1,175 | 1,209 | 881 | 766 | 824 | 804 | 691 | 611 |
| Liabilities | 486 | 474 | 209 | 441 | 132 | 104 | 105 | 75.23 | 54.98 | 44.04 |
| Book Value | 918 | 1,089 | 966 | 768 | 748 | 662 | 719 | 729 | 636 | 567 |
Company Profile
Company Details
| Full Name | Myriad Genetics, Inc. |
| Country | United States |
| Employees | 2,700 |
| CEO | Paul J. Diaz |
Stock Information
| Ticker Symbol | MYGN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: MYGN |
| IPO Date | October 5, 1995 |
Description
Myriad Genetics, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.